Adaptimmune Therapeutics PLC
(NAS:ADAP)
$
0.7937
0 (0%)
Market Cap: 202.99 Mil
Enterprise Value: 35.54 Mil
PE Ratio: 0
PB Ratio: 2.09
GF Score: 62/100 Adaptimmune Therapeutics PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020 / 12:00PM GMT
Release Date Price:
$10.75
(-0.28%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. Before we start, please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
For this session, we have from Adaptimmune, CEO, Adrian Rawcliffe; CFO, Gavin Wood; and CMO, Elliot Norry. Welcome, everyone.
Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director
Hi. Great to be here.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot